Bristol Excedrin first quarter sales up 38% to $66 mil. on migraine indication.
This article was originally published in The Tan Sheet
EXCEDRIN SALES JUMP 38% TO $66 MIL. ON EXCEDRIN MIGRAINE APPROVAL in January, but overall in the first quarter, consumer medicine sales dropped 4%, Bristol-Myers Squibb announced April 21. Consumer medicine sales worldwide would have increased by 1% excluding the effect of foreign currencies, BMS noted. International consumer medicine sales dropped 6% (2% excluding foreign exchange). The decline overseas reflects the "low level of influenza in Europe" compared to the prior year, the company said.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC